Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genflow Biosciences Plc ( (GB:GENF) ) just unveiled an announcement.
Genflow Biosciences Plc has confirmed approximately €4 million in non-dilutive financial support from the Wallonia Region of Belgium to support the development of its lead gene therapy candidate, GF-1002, aimed at treating Metabolic Associated Steatohepatitis (MASH). This funding spans a three-year development program and aligns with Genflow’s clinical roadmap, ensuring no delays in research or development activities. The company’s CEO, Dr. Eric Leire, emphasized the significance of this endorsement and the uninterrupted progress of the GF-1002 program, which is crucial for advancing the treatment of MASH, a chronic liver disease with no effective treatments.
More about Genflow Biosciences Plc
Genflow Biosciences Plc, founded in 2020, is a UK-based biotechnology company with R&D facilities in Belgium. It focuses on pioneering gene therapies to decelerate the aging process, aiming to promote longer and healthier lives. The company’s lead compound, GF-1002, is a gene therapy candidate targeting the SIRT6 gene, which has shown promising preclinical results. Genflow is conducting a 12-month proof-of-concept clinical trial in aged dogs and plans to explore GF-1002’s potential in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH), a prevalent chronic liver disease.
Average Trading Volume: 3,999,522
Technical Sentiment Signal: Sell
For detailed information about GENF stock, go to TipRanks’ Stock Analysis page.